Role of Exercise and Energy Conservation in the Management of Fatigue in Patients with NSCLC Receiving Immune-Oncology Therapy

2021 Year in Review: Non–Small-Cell Lung Cancer —December 29, 2021

Categories:

Lung Cancer

Cancer-related fatigue occurs on most days over the course of the disease, lasts at least 2 weeks, and interferes with daily activities.1 Throughout the course of the disease, fatigue is the most frequently reported symptom in patients with lung cancer.1

Antineoplastic therapies are known to cause treatment-related tiredness, complicating an already difficult situation. Fatigue is the most common adverse event in patients on immune checkpoint inhibitors, which are the new standard of care in non–small-cell lung cancer (NSCLC) treatment.1

Exercise and physical activity, according to a significant body of data, improves the general health of patients with cancer and may help them live longer.2 Physical activity has been linked to a lower incidence of a variety of cancers in humans, and some evidence suggests that it may have a clinical benefit for patients with cancer.3 Exercise causes immune system cells to mobilize and redistribute to different bodily compartments, and exercise has been demonstrated to cause immunologic alterations in the tumor microenvironment in preclinical models. This suggests that combining exercise and immunotherapy may have a synergistic impact.3 The advantages of exercise include physical well-being, calm, freedom, relaxation, and improved sleep quality.

Given the substantial link between exercise and better outcomes in patients with cancer, strengthening systemic immunity and patient immunologic responses through exercise could be a complementary method to boosting immunotherapy responses, allowing for a more effective therapeutic response.2 Numerous studies have recently been published that provide some intriguing information about how exercise affects immune cell populations and function. The scientific premise that physical activity and exercise can help the immune system recover and optimize its responses to cancer is well-documented.2

The fatigue caused by cancer and further fatigue caused by immune checkpoint inhibitor treatment is an unfortunate aspect of cancer, including NSCLC. To maintain a patient’s functionality, nurses should become proactive advocates for physical activity throughout and after therapy. A well-thought-out progressive program of restorative exercise and energy-saving skills can help manage fatigue as a therapeutic complement to antineoplastic treatment. Aerobic exercise for at least 30 minutes a day for 5 days per week is an ideal exercise routine for patients with cancer to strive toward, if they can manage.3

References

  1. Almeida C, Chemela R. The role of physical exercise and energy conservation in the management of fatigue in NSCLC patients under IO. Ann Oncol. 2021;32(suppl 5):S1278.
  2. Gustafson MP, Wheatley-Guy CM, Rosenthal AC, et al. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J ImmunoTherapy Cancer. 2021;9:e001872.
  3. Olofsson GH, Jensen AWP, Idorn M, Straten PT. Exercise oncology and immune-oncology; a (future) dynamic duo. Int J Mol Sci. 2020;21:3816.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country